var data={"title":"Eosinophilic gastroenteritis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Eosinophilic gastroenteritis</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/contributors\" class=\"contributor contributor_credentials\">Nirmala Gonsalves, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/contributors\" class=\"contributor contributor_credentials\">Lawrence S Friedman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/contributors\" class=\"contributor contributor_credentials\">Shilpa Grover, MD, MPH, AGAF</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 02, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Eosinophilic gastroenteritis (EGE) belongs to a group of diseases that includes eosinophilic esophagitis, gastritis, enteritis, and colitis, collectively referred to as &quot;eosinophilic gastrointestinal disorders&quot; [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/1\" class=\"abstract_t\">1</a>].</p><p>This topic will review the clinical manifestations, diagnosis, and management of EGE. Eosinophilic esophagitis is discussed in detail, separately. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-eosinophilic-esophagitis\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of eosinophilic esophagitis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H775893728\"><span class=\"h1\">DEFINITION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Eosinophilic gastroenteritis (EGE) is an inflammatory disorder characterized by eosinophilic infiltration of the stomach and duodenum, and in some cases, the esophagus and colon without any known cause of eosinophilia.</p><p class=\"headingAnchor\" id=\"H259960030\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are limited data on the prevalence of eosinophilic gastroenteritis (EGE). The prevalence of EGE in the United States is estimated to be 22 to 28 per 100,000 persons [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/2\" class=\"abstract_t\">2</a>]. EGE can affect patients of any age, but typically presents in the third through fifth decades and has a peak age of onset in the third decade [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/3-5\" class=\"abstract_t\">3-5</a>]. A slight male predominance has been reported.</p><p class=\"headingAnchor\" id=\"H259959758\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The pathogenesis of eosinophilic gastroenteritis (EGE) is not well understood. Multiple epidemiologic and clinical features suggest an allergic component [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/3,6,7\" class=\"abstract_t\">3,6,7</a>]. In addition, patients with EGE have elevated serum immunoglobulin E (IgE) levels [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/7-10\" class=\"abstract_t\">7-10</a>]. (See <a href=\"#H259957844\" class=\"local\">'Clinical manifestations'</a> below and <a href=\"#H259957467\" class=\"local\">'Laboratory findings'</a> below.)</p><p>Although the role of food allergy in EGE has not been as clearly defined as with eosinophilic esophagitis, several reports have described an improvement in EGE disease activity with an elemental or elimination diet [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/11-14\" class=\"abstract_t\">11-14</a>]. In allergic EGE patients, but not those with conventional anaphylactic food allergy, a population of interleukin-5 (IL-5) expressing food allergen-specific T helper 2 (Th2) cells have been identified [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/15\" class=\"abstract_t\">15</a>]. This suggests that food exposure activates and drives the differentiation of IL-5+ Th2 cells in EGE, leading to gut eosinophilia. The eotaxin family of chemokines appears to play a central role in the recruitment of eosinophils into the gut in response to antigen challenge [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/16\" class=\"abstract_t\">16</a>]. Once eosinophils are recruited to the gastrointestinal tract, they are able to persist through the release of eosinophil-active cytokines, such as IL-3, IL-5, and granulocyte macrophage-colony stimulating factor [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/17\" class=\"abstract_t\">17</a>]. Eosinophils can also cause local inflammation by release of eosinophil major basic protein, a cytotoxic cationic protein [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/18\" class=\"abstract_t\">18</a>].</p><p class=\"headingAnchor\" id=\"H259957844\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The entire gastrointestinal tract from esophagus to colon can be affected in patients with eosinophilic gastroenteritis (EGE) [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/3,19-21\" class=\"abstract_t\">3,19-21</a>]. While studies have suggested that EGE has a predilection for the distal antrum and proximal small bowel, this may reflect sampling bias because of the accessibility of these areas for biopsy [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/8\" class=\"abstract_t\">8</a>].</p><p>Approximately one-half of patients with EGE have a history of an allergic disease including asthma, defined food sensitivities, eczema, or rhinitis [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/3,6,7\" class=\"abstract_t\">3,6,7</a>]. The clinical features of EGE are related to the location, extent, and layer(s) of bowel with eosinophilic infiltration [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/8\" class=\"abstract_t\">8</a>].</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h2\">Mucosal disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Eosinophilic mucosal infiltration produces nonspecific symptoms that depend upon the area of the gastrointestinal tract that is involved. In a retrospective study of 40 patients with mucosal EGE, the most common symptoms were abdominal pain, nausea, vomiting, early satiety, and diarrhea [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/3\" class=\"abstract_t\">3</a>]. Only one-third of patients had a weight loss of 2.4 kg or more. Patients with diffuse small bowel disease can develop malabsorption, protein-losing enteropathy, and failure to thrive [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/8,22\" class=\"abstract_t\">8,22</a>].</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Muscular layer disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Eosinophilic infiltration of the muscle layer of the gastrointestinal tract results in wall thickening and impaired motility. Patients may present with symptoms of intestinal obstruction, including nausea, vomiting, and abdominal distention [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/3,8,22\" class=\"abstract_t\">3,8,22</a>]. Patients with pseudoachalasia or an esophageal stricture may present with dysphagia and regurgitation of undigested food. Eosinophilic infiltration may result in perforation or obstruction of the gastric outlet, small bowel, or rarely the colon [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/3,6-8,10,22-25\" class=\"abstract_t\">3,6-8,10,22-25</a>]. (See <a href=\"topic.htm?path=achalasia-pathogenesis-clinical-manifestations-and-diagnosis#H198500171\" class=\"medical medical_review\">&quot;Achalasia: Pathogenesis, clinical manifestations, and diagnosis&quot;, section on 'Clinical manifestations'</a>.)</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Subserosal disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with subserosal EGE present with isolated ascites or ascites in combination with symptoms characteristic of mucosal or muscular EGE [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/3\" class=\"abstract_t\">3</a>]. An eosinophilic pleural effusion may also be present [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/22\" class=\"abstract_t\">22</a>]. (See <a href=\"topic.htm?path=pleural-fluid-eosinophilia\" class=\"medical medical_review\">&quot;Pleural fluid eosinophilia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H259957467\"><span class=\"h1\">LABORATORY FINDINGS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Various laboratory tests may be abnormal in patients with eosinophilic gastroenteritis (EGE):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Peripheral eosinophil counts are usually elevated in patients with EGE, but may be normal in approximately 20 percent of patients [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/3\" class=\"abstract_t\">3</a>]. Peripheral eosinophil counts range from 5 to 35 percent with an average absolute eosinophil count of 1000 <span class=\"nowrap\">cells/microL</span> [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/26\" class=\"abstract_t\">26</a>]. Mucosal and subserosal EGE are characterized by higher eosinophil counts as compared with EGE that involves the muscular layer.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with malabsorption due to mucosal EGE may have an abnormal D-xylose test due to carbohydrate malabsorption and increased fecal fat excretion with prolonged prothrombin time [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/8,22\" class=\"abstract_t\">8,22</a>]. Increased mucosal permeability may result in protein-losing enteropathy and resultant hypoalbuminemia. Anemia may result from impaired iron absorption and occult gastrointestinal bleeding [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/8,9,22\" class=\"abstract_t\">8,9,22</a>]. (See <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-malabsorption#H3\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of malabsorption&quot;, section on 'Diagnosis'</a> and <a href=\"topic.htm?path=protein-losing-gastroenteropathy#H5\" class=\"medical medical_review\">&quot;Protein-losing gastroenteropathy&quot;, section on 'Nonerosive gastrointestinal diseases'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>EGE is often associated with iron deficiency. The erythrocyte sedimentation rate is usually normal, but can be modestly elevated in approximately 25 percent of patients [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/3,22\" class=\"abstract_t\">3,22</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Serum immunoglobulin E (IgE) levels can be elevated, especially in children [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/3,7,8,10\" class=\"abstract_t\">3,7,8,10</a>].</p><p/><p class=\"headingAnchor\" id=\"H259957890\"><span class=\"h1\">IMAGING FINDINGS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Imaging (eg, <a href=\"topic.htm?path=barium-drug-information\" class=\"drug drug_general\">barium</a> studies, abdominal computed tomography scan, or magnetic resonance imaging) of the gastrointestinal tract may reveal thickening or nodularity in the antrum and thickened or &quot;saw-tooth&quot; mucosa in the small bowel [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/23\" class=\"abstract_t\">23</a>]. Imaging in patients with muscular involvement may reveal irregular luminal narrowing, especially in the distal antrum and proximal small bowel. However, these findings are neither sensitive nor specific for EGE.</p><p class=\"headingAnchor\" id=\"H273960934\"><span class=\"h1\">EVALUATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Eosinophilic gastroenteritis (EGE) should be suspected in a patient with abdominal pain, nausea, vomiting, early satiety, diarrhea, weight loss, or ascites associated with peripheral eosinophilia (eosinophil count &gt;500 <span class=\"nowrap\">eosinophils/microL</span> in the peripheral blood), <span class=\"nowrap\">and/or</span> a history of food allergy or intolerance. Evaluation of a patient with suspected EGE serves to exclude other causes of eosinophilia and establish the diagnosis of EGE.</p><p class=\"headingAnchor\" id=\"H273961287\"><span class=\"h2\">Diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of EGE is based on the presence of eosinophilic infiltration of the gastrointestinal tract on biopsy <span class=\"nowrap\">and/or</span> eosinophilic ascitic fluid, lack of involvement of other organs, and absence of other causes of intestinal eosinophilia.</p><p class=\"headingAnchor\" id=\"H697190562\"><span class=\"h3\">History and physical examination</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Drug-induced peripheral eosinophilia should be excluded with a detailed review of past, current, and over-the-counter medications and dietary and herbal supplements. Dietary history should include the ingestion of raw or undercooked meat and history of residence in or recent travel to parasite endemic areas.</p><p>The physical examination should focus on identifying lesions that suggest a possible cause of eosinophilia and determining the presence of extraintestinal organ involvement, which would suggest an alternative diagnosis. We specifically examine the skin, eyes, nose, lymph nodes, and abdomen in addition to performing a cardiovascular, respiratory, and neurologic examination. (See <a href=\"#H259957265\" class=\"local\">'Differential diagnosis'</a> below.)</p><p class=\"headingAnchor\" id=\"H273960927\"><span class=\"h3\">Laboratory evaluation and other testing</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Laboratory evaluation should include a complete blood count with differential to determine the absolute eosinophil count. In addition, we also obtain serum electrolytes, albumin, serum iron, iron binding capacity, ferritin, and markers of inflammation, erythrocyte sedimentation rate, or C-reactive protein. (See <a href=\"#H259957467\" class=\"local\">'Laboratory findings'</a> above.)</p><p/><p class=\"bulletIndent1\">As eosinophilia can be caused by a number of conditions other than EGE, we perform the following initial tests in patients with peripheral eosinophilia, to exclude other etiologies:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Review of the peripheral blood smear (for immature white blood cells, dysplastic features)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Serum chemistries for evidence of adrenal dysfunction (eg, hyponatremia, hyperkalemia)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Serum B12 level (elevated in myeloproliferative neoplasms) </p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Serum immunoglobulin subsets, as evidence of immune deficiency (immunoglobulin [Ig] E, IgM, IgG)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Human immunodeficiency virus (HIV) serology</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Serum tryptase (elevated in systemic mastocytosis and some neoplastic hypereosinophilic syndromes)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Flow cytometry for lymphocyte subsets (may show clonality in lymphoid lymphoma or leukemia; reduced CD4 count in <span class=\"nowrap\">HIV/acquired</span> immunodeficiency syndrome [AIDS]; selective deficiencies in immunodeficiency syndromes) (see <a href=\"topic.htm?path=approach-to-the-patient-with-unexplained-eosinophilia#H7341711\" class=\"medical medical_review\">&quot;Approach to the patient with unexplained eosinophilia&quot;, section on 'Major causes of eosinophilia'</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Stool studies and serologic studies should be performed to exclude a parasitic infection. This should include microscopy for ova and parasites and serologies for <em>Strongyloides</em> and <em>Toxocara</em> species. Additional testing for antibodies to fungi and parasites (eg, <em>Coccidioides, Echinococcus, Schistosoma, Trichinella spiralis</em>) may be indicated in patients with a history of travel to or residence in endemic areas. (See <a href=\"#H259957265\" class=\"local\">'Differential diagnosis'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients with ascites, ascitic fluid analysis should include cell count with differential, Gram stain, culture, acid-fast bacillus stain, fungal and mycobacterial cultures, and cytology. Although there are no established criteria for ascitic fluid eosinophilia, studies have reported markedly elevated eosinophil counts (up to 88 percent) in patients with EGE [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/8\" class=\"abstract_t\">8</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>As the presence of other organ involvement excludes the diagnosis of EGE, we also perform the following testing:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Renal function (serum chemistries, creatinine, urinalysis)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Hepatic function (liver enzymes, total bilirubin)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Cardiac function (troponin, electrocardiogram); those with elevated troponin should have an echocardiogram</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Pulmonary function</p><p/><p class=\"headingAnchor\" id=\"H273961345\"><span class=\"h3\">Endoscopy and biopsy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Endoscopic findings of mucosal disease are nonspecific and include nodular or polypoid gastric mucosa, erythema, or erosions (<a href=\"image.htm?imageKey=GAST%2F50409\" class=\"graphic graphic_picture graphicRef50409 \">picture 1</a>). The diagnosis of mucosal EGE is established by the presence of more than the number of expected eosinophils on microscopic examination of biopsies of the gastrointestinal tract (<a href=\"image.htm?imageKey=GAST%2F50254\" class=\"graphic graphic_picture graphicRef50254 \">picture 2</a>) [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/3,9,27,28\" class=\"abstract_t\">3,9,27,28</a>]. As there is no defined cutoff for the number of <span class=\"nowrap\">eosinophils/high-power</span> field to diagnose EGE, the diagnosis should be confirmed by an experienced gastrointestinal pathologist to assess if the number of eosinophils is more than expected for a particular area. Because the stomach and duodenum are the most commonly affected sites, endoscopic evaluation is typically limited to the upper gastrointestinal tract. In patients with significant diarrhea, we also perform a colonoscopy. As EGE can be patchy in patients with mucosal disease, it is important that the following be performed:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Biopsies should be taken from both normal and abnormal-appearing mucosa, as normal-appearing mucosa can demonstrate eosinophilic inflammation [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/28\" class=\"abstract_t\">28</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Multiple biopsy samples (at least four to five biopsies per site) should be taken from both the stomach and small intestine, with additional biopsies of areas with visual abnormalities [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/9,29\" class=\"abstract_t\">9,29</a>].</p><p/><p>In patients with mucosal disease, upper endoscopy with biopsy of the stomach and small intestine is diagnostic in at least 80 percent of patients [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/3,9\" class=\"abstract_t\">3,9</a>]. However, it is important to note that mucosal biopsies are normal in patients with muscular or subserosal disease [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/3,28\" class=\"abstract_t\">3,28</a>].</p><p class=\"headingAnchor\" id=\"H344301069\"><span class=\"h3\">Full-thickness biopsy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>As negative endoscopic mucosal biopsies do not definitively rule out muscular or subserosal EGE, laparoscopic full-thickness biopsy is necessary to establish the diagnosis. In patients with bowel wall thickening <span class=\"nowrap\">and/or</span> obstruction, this also serves to exclude an underlying malignancy.</p><p class=\"headingAnchor\" id=\"H259957265\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Other diseases in which gastrointestinal symptoms are associated with peripheral eosinophilia can be distinguished from eosinophilic gastroenteritis (EGE) based on the clinical presentation, laboratory tests, <span class=\"nowrap\">and/or</span> biopsies of the gastrointestinal tract.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Intestinal parasites</strong> &ndash; Infection with <em>Ancylostoma, Anisakis, Ascaris, Strongyloides, Toxocara, Trichiura, Capillaria</em>, <em>Basidiobolomycosis</em>, and <em>Trichinella</em> can all cause gastrointestinal symptoms and peripheral eosinophilia. Infection with the dog hookworm, <em>Ancylostoma caninum</em>, can mimic EGE clinically and pathologically with eosinophilic infiltration of the gut wall and ascites [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/30\" class=\"abstract_t\">30</a>]. However, a parasitic infection can be excluded by examination of the stool for ova or parasites <span class=\"nowrap\">and/or</span> serologic testing. In addition, stool examination in patients with a parasitic infection may reveal Charcot-Leyden crystals, which are the product of eosinophil granules. (See <a href=\"topic.htm?path=approach-to-the-patient-with-unexplained-eosinophilia\" class=\"medical medical_review\">&quot;Approach to the patient with unexplained eosinophilia&quot;</a> and <a href=\"topic.htm?path=eosinophil-biology-and-causes-of-eosinophilia#H261622134\" class=\"medical medical_review\">&quot;Eosinophil biology and causes of eosinophilia&quot;, section on 'Disorders with eosinophilic involvement of specific organs'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Malignancy</strong> &ndash; Lymphoma, gastric cancer, and colon cancer can present with obstruction, peripheral eosinophilia, and a mass or bowel wall thickening on imaging. However, a malignancy can be differentiated from EGE by endoscopic or full-thickness biopsy. (See <a href=\"topic.htm?path=clinical-features-diagnosis-and-staging-of-gastric-cancer\" class=\"medical medical_review\">&quot;Clinical features, diagnosis, and staging of gastric cancer&quot;</a> and <a href=\"topic.htm?path=clinical-presentation-and-diagnosis-of-primary-gastrointestinal-lymphomas\" class=\"medical medical_review\">&quot;Clinical presentation and diagnosis of primary gastrointestinal lymphomas&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Inflammatory bowel disease</strong> &ndash; Rarely, Crohn disease may be associated with peripheral eosinophilia <span class=\"nowrap\">and/or</span> an eosinophil-rich tissue infiltrate. Crohn disease can usually be differentiated from EGE by the presence of typical architectural distortion, focally enhanced neutrophilic exudates, and granulomas. (See <a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-prognosis-of-crohn-disease-in-adults#H12689148\" class=\"medical medical_review\">&quot;Clinical manifestations, diagnosis and prognosis of Crohn disease in adults&quot;, section on 'Diagnosis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Hypereosinophilic syndrome</strong> &ndash; Hypereosinophilic syndrome (HES) is an idiopathic condition associated with marked peripheral eosinophilia and may rarely present with predominant gastrointestinal symptoms. Many EGE patients may fulfill the diagnostic criterion for HES (absolute eosinophil count &ge;1500 <span class=\"nowrap\">cells/mL</span> present for over six months). However, in contrast with EGE, HES involves multiple organ systems (eg, heart, lungs, brain, and kidneys) [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/31\" class=\"abstract_t\">31</a>]. (See <a href=\"topic.htm?path=hypereosinophilic-syndromes-clinical-manifestations-pathophysiology-and-diagnosis#H13\" class=\"medical medical_review\">&quot;Hypereosinophilic syndromes: Clinical manifestations, pathophysiology, and diagnosis&quot;, section on 'Clinical features'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Polyarteritis nodosa</strong> &ndash; Polyarteritis nodosa (PAN) is associated with peripheral eosinophilia and abdominal pain. Nodular masses may also be visualized in the stomach, but, in contrast with EGE, patients with PAN have systemic manifestations, a markedly elevated erythrocyte sedimentation rate, and on biopsy the eosinophilia is perivascular [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/22\" class=\"abstract_t\">22</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-polyarteritis-nodosa-in-adults#H7\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of polyarteritis nodosa in adults&quot;, section on 'Clinical features'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Eosinophilic granulomatosis with polyangiitis</strong> &ndash; An EGE, characterized by abdominal pain, diarrhea, gastrointestinal bleeding, and colitis, may precede or coincide with the vasculitic phase of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Asthma is the cardinal feature of this disorder (occurring in more than 95 percent of patients) and usually precedes the vasculitic phase by approximately 8 to 10 years. (See <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss#H2\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)&quot;, section on 'Clinical features'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Eosinophilic granuloma (Langerhans cell histiocytosis)</strong> &ndash; Eosinophilic granuloma, like EGE, can present as a gastric antral mass. However, it can be differentiated from EGE by its typical granulomatous appearance on biopsy [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/32\" class=\"abstract_t\">32</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-langerhans-cell-histiocytosis#H452652235\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis&quot;, section on 'Pathologic features'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H259957271\"><span class=\"h1\">DISEASE COURSE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The natural history and disease course of EGE are not well defined as studies are limited to case reports and small series. While some untreated patients with EGE have been reported to rarely remit spontaneously, other patients may progress to severe malabsorption and malnutrition [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/8,28\" class=\"abstract_t\">8,28</a>]. In a small percentage of patients, EGE remits completely with treatment. Other patients have periodic flares months to years after the initial episode or require long-term maintenance treatment.</p><p class=\"headingAnchor\" id=\"H860165348\"><span class=\"h1\">MANAGEMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment of eosinophilic gastroenteritis (EGE) is based on limited evidence and varies based upon the severity of symptoms and the presence of malabsorption (<a href=\"image.htm?imageKey=GAST%2F76166\" class=\"graphic graphic_table graphicRef76166 \">table 1</a>). (See <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-malabsorption\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of malabsorption&quot;</a> and <a href=\"topic.htm?path=overview-of-the-treatment-of-malabsorption\" class=\"medical medical_review\">&quot;Overview of the treatment of malabsorption&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H775893880\"><span class=\"h2\">lnitial therapy</span></p><p class=\"headingAnchor\" id=\"H259960214\"><span class=\"h3\">Dietary therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In patients who are symptomatic or have evidence of malabsorption, we suggest an initial attempt at an empiric elimination diet, a six-food elimination diet, or an elemental diet. Based on studies in eosinophilic esophagitis, such diets should be undertaken for a minimum of four to six weeks [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/33\" class=\"abstract_t\">33</a>]. Whether this approach will yield similar results in EGE is yet to be determined.</p><p>Patients on an elemental diet are placed on an elemental formula, which eliminates all potential food allergens. The empiric elimination diet consists of avoidance of foods that most commonly cause immediate hypersensitivity in a population. The six-food elimination diet is the most commonly used empiric elimination diet. Specific foods that are avoided in the six-food elimination diet include soy, wheat, egg, milk, <span class=\"nowrap\">peanut/tree</span> nuts, and <span class=\"nowrap\">fish/shellfish</span> [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/34\" class=\"abstract_t\">34</a>].</p><p>The main limitation of dietary therapy is patient compliance. Dietary therapy should be pursued in motivated patients and under the guidance of a dietitian trained in eosinophilic gastrointestinal disorders. If a history of environmental allergens is identified, these should be treated in conjunction with the diet. The role of the dietician includes patient education on the use of antigen-free foods, allergen avoidance, and food suggestions to ensure a nutritionally adequate diet. In addition, vitamin supplements may be necessary in patients who avoid foods containing calcium and vitamin D.</p><p>We follow patients based upon their symptoms and changes in peripheral eosinophilia. We check absolute eosinophil counts four to six weeks after instituting a dietary change. In patients with a peripheral eosinophilia, a reduction of &gt;50 percent may be considered a response. However, the use of peripheral blood eosinophil count to monitor responses to dietary therapy is not useful in patients lacking peripheral eosinophilia. In addition, patients may have other allergic diseases (eg, atopic dermatitis, asthma) driving peripheral eosinophilia that do not respond to dietary therapy. We perform a repeat endoscopy with biopsies when there is uncertainty regarding the response to treatment <span class=\"nowrap\">and/or</span> degree of ongoing disease activity. If the dietary changes are successful at reducing symptoms and either peripheral eosinophilia or tissue eosinophilia, foods can be added back slowly in a systematic fashion from least allergenic to most allergenic.</p><p>Preliminary results of a trial in adults with EGE demonstrated clinical remission with a six-week course of dietary elimination. In this study, three of seven adults undergoing an empiric six-food elimination diet and all six adults undergoing an elemental diet had significant reduction in symptoms, complete histologic remission, endoscopic improvement, and normalization of peripheral eosinophilia within six weeks [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/13\" class=\"abstract_t\">13</a>].</p><p>Although food hypersensitivity plays an important role in EGE pathogenesis, no food allergy test (skin, patch, or allergen-specific immunoglobulin [Ig] E) has been shown to effectively identify specific culprit foods leading to clinical improvement of EGE symptoms or tissue eosinophilia. Thus, at present there is no evidence to support routine food allergy testing of EGE patients for use in clinical decision-making [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/35\" class=\"abstract_t\">35</a>].</p><p class=\"headingAnchor\" id=\"H259960226\"><span class=\"h3\">Glucocorticoids</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>If dietary measures do not result in improvement in symptoms, we suggest a trial of <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> (typically 20 to 40 <span class=\"nowrap\">mg/day)</span>. However, evidence to support the use of glucocorticoids is limited to small series of patients [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/12,27\" class=\"abstract_t\">12,27</a>]. Improvement in symptoms usually occurs within two weeks regardless of the layer of bowel involved [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/22,27\" class=\"abstract_t\">22,27</a>]. Prednisone should then be tapered rapidly over the next two weeks. The goal of glucocorticoid therapy is to use the minimum dose needed to ameliorate severe EGE symptoms, rather than use high doses to control tissue eosinophilia, as fibrosis is much less common in EGE as compared with eosinophilic esophagitis and high doses of glucocorticoids are associated with systemic side effects. (See <a href=\"topic.htm?path=major-side-effects-of-systemic-glucocorticoids#H5\" class=\"medical medical_review\">&quot;Major side effects of systemic glucocorticoids&quot;, section on 'Organ-based toxicity of systemic glucocorticoids'</a>.)</p><p>However, some patients require more prolonged therapy (up to several months) with a gradual oral glucocorticoid taper to produce complete resolution of symptoms [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/19,27\" class=\"abstract_t\">19,27</a>] &#160; Patients not responding to oral <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> should be treated with equivalent intravenous glucocorticoids. Patients who fail to respond to intravenous glucocorticoids should undergo careful reevaluation to rule out the presence of an underlying infection or alternate diagnoses including Crohn disease. (See <a href=\"#H259957265\" class=\"local\">'Differential diagnosis'</a> above.)</p><p class=\"headingAnchor\" id=\"H775893873\"><span class=\"h2\">Recurrent symptoms</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients who experience periodic flares months to years after the initial episode can be treated with another short course of oral <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a>, 20 to 40 <span class=\"nowrap\">mg/day,</span> followed by a rapid taper [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/27\" class=\"abstract_t\">27</a>].</p><p>In the majority of patients with EGE who experience recurrent symptoms during or immediately after the <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> taper, long-term, low-dose maintenance therapy with prednisone (eg, 5 to 10 <span class=\"nowrap\">mg/day)</span> is needed [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/8,22,27\" class=\"abstract_t\">8,22,27</a>]. Alternatively, the controlled ileal release capsules may provide effective therapy in patients with distal disease. Successful transition from oral, conventional glucocorticoids to <a href=\"topic.htm?path=budesonide-drug-information\" class=\"drug drug_general\">budesonide</a> (nonenterically coated) has been reported in patients with EGE involving the gastric antrum and small intestine [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/36-38\" class=\"abstract_t\">36-38</a>]. It should be noted that the formulation of budesonide available for gastrointestinal use is in controlled ileal release capsules, which do not release until the terminal ileum, largely bypassing the upper gastrointestinal tract. Case reports suggest that such budesonide formulations have been used off-label to target the upper gastrointestinal tract by dissolving the controlled release capsules in water.</p><p class=\"headingAnchor\" id=\"H860165540\"><span class=\"h2\">Other therapies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Several other approaches have been described in case reports or small series to treat recurrent or refractory symptoms. However, none of these agents can be recommended for routine use based on limited available data.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=cromolyn-sodium-cromoglicate-drug-information\" class=\"drug drug_general\">Cromolyn</a> (800 <span class=\"nowrap\">mg/day</span> in four divided doses) has been effective for short- and long-term management of EGE in some case reports, but conflicting results have also been reported [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/3,39,40\" class=\"abstract_t\">3,39,40</a>]. Cromolyn works by preventing the release of mast cell mediators, including histamine, platelet-activating factor, and leukotrienes, and is also thought to reduce absorption of antigens by the small intestine.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ketotifen-drug-information\" class=\"drug drug_general\">Ketotifen</a> is an H1-antihistamine and mast cell stabilizer that has been associated with an improvement in clinical symptoms and tissue eosinophilia in small series of patients [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/41-43\" class=\"abstract_t\">41-43</a>]. In adults, it is administered at a starting dose of 1 mg at night and increased to 2 to 4 mg per day for one to four months. Although ketotifen is available in some countries, it is not available in the United States.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Leukotriene antagonist <a href=\"topic.htm?path=montelukast-drug-information\" class=\"drug drug_general\">montelukast</a> has been reported to be effective in some case reports but not in others [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/44-47\" class=\"abstract_t\">44-47</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A clinical response to suplatast tosilate, which is a novel antiallergic drug that suppresses cytokine production, including interleukin (IL)-4 and IL-5 from T helper 2 (Th2) cells, was described in a single patient [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/48\" class=\"abstract_t\">48</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Humanized anti-IL-5 antibody treatment was associated with reduced peripheral and tissue eosinophil counts in a preliminary report of four patients, but had no effect on symptoms [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/49\" class=\"abstract_t\">49</a>]. In addition, rebound eosinophilia has been observed after treatment is discontinued [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/50\" class=\"abstract_t\">50</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=omalizumab-drug-information\" class=\"drug drug_general\">Omalizumab</a> is an anti-IgE monoclonal antibody that has been associated with a significant improvement in symptoms and measures of IgE-mediated allergy in a case series that included nine patients [<a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/4\" class=\"abstract_t\">4</a>]. Tissue eosinophilia was reduced, but the reduction was not statistically significant.</p><p/><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Eosinophilic gastroenteritis (EGE) is an inflammatory disorder characterized by eosinophilic infiltration of the stomach and duodenum, and, in some cases, the esophagus and colon without any known cause of eosinophilia. (See <a href=\"#H775893728\" class=\"local\">'Definition'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>EGE is a rare disorder that can affect patients of any age, but typically presents in the third through fifth decades. The pathogenesis of EGE is not well understood, but epidemiologic and clinical features suggest an allergic component. Approximately one-half of patients have a history of allergic disease including asthma, defined food sensitivities, eczema, or rhinitis. (See <a href=\"#H259959758\" class=\"local\">'Pathogenesis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The signs and symptoms of EGE are related to the location, extent, and layer(s) of bowel with eosinophilic infiltration. The most common symptoms of eosinophilic mucosal infiltration are abdominal pain, nausea, early satiety, vomiting, diarrhea, and weight loss. Patients with eosinophilic infiltration of the muscle layer may have symptoms of intestinal obstruction with nausea, vomiting, and abdominal distention. Patients with subserosal EGE may present with isolated ascites or ascites in combination with symptoms characteristic of mucosal or muscular EGE. (See <a href=\"#H259957844\" class=\"local\">'Clinical manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>EGE should be suspected in a patient with abdominal pain, nausea, vomiting, early satiety, diarrhea, weight loss, or ascites that are associated with peripheral eosinophilia <span class=\"nowrap\">and/or</span> a history of food allergy or intolerance. The diagnosis of EGE is based on the presence of eosinophilic infiltration of the gastrointestinal tract on biopsy <span class=\"nowrap\">and/or</span> eosinophilic ascitic fluid, lack of involvement of other organs, and absence of other causes of intestinal eosinophilia by history, laboratory evaluation, and other testing. (See <a href=\"#H273960934\" class=\"local\">'Evaluation'</a> above and <a href=\"#H259957265\" class=\"local\">'Differential diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In motivated patients who are symptomatic or have evidence of malabsorption (<a href=\"image.htm?imageKey=GAST%2F76166\" class=\"graphic graphic_table graphicRef76166 \">table 1</a>), we suggest dietary therapy with an empiric elimination diet (eg, a six-food elimination diet), or an elemental diet (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). Dietary therapy should be pursued for a minimum of four to six weeks and under the guidance of a dietitian trained in eosinophilic gastrointestinal disorders.</p><p/><p class=\"bulletIndent1\">We follow patients based upon their symptoms and the changes in peripheral eosinophilia. We perform a repeat endoscopy when there is uncertainty regarding the response to treatment <span class=\"nowrap\">and/or</span> degree of ongoing disease activity. If the dietary changes are successful at reducing symptoms and either the peripheral eosinophil count by &gt;50 percent or tissue eosinophilia, then foods can be added back slowly in a systematic fashion from least allergenic to most allergenic. (See <a href=\"topic.htm?path=treatment-of-eosinophilic-esophagitis\" class=\"medical medical_review\">&quot;Treatment of eosinophilic esophagitis&quot;</a> and <a href=\"#H259960214\" class=\"local\">'Dietary therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients who decline a dietary approach or whose symptoms do not improve after dietary therapy for six weeks, we suggest a trial of <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> (20 to 40 <span class=\"nowrap\">mg/day)</span> (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). Improvement usually occurs within two weeks regardless of the layer of bowel involved. Prednisone should then be tapered rapidly over the next two weeks. However, some patients require prolonged therapy (up to several months) for resolution of symptoms. Patients who relapse immediately after steroid cessation may need long-term, low-dose maintenance therapy with prednisone or <a href=\"topic.htm?path=budesonide-drug-information\" class=\"drug drug_general\">budesonide</a>. (See <a href=\"#H259960226\" class=\"local\">'Glucocorticoids'</a> above and <a href=\"#H860165540\" class=\"local\">'Other therapies'</a> above.)</p><p/><p class=\"headingAnchor\" id=\"H2099131980\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The UpToDate editorial staff would like to thank Dr. Calman Prussin, MD, for his contributions as author to prior versions of this topic review. </p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/1\" class=\"nounderline abstract_t\">Rothenberg ME. Eosinophilic gastrointestinal disorders (EGID). J Allergy Clin Immunol 2004; 113:11.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/2\" class=\"nounderline abstract_t\">Spergel JM, Book WM, Mays E, et al. Variation in prevalence, diagnostic criteria, and initial management options for eosinophilic gastrointestinal diseases in the United States. J Pediatr Gastroenterol Nutr 2011; 52:300.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/3\" class=\"nounderline abstract_t\">Talley NJ, Shorter RG, Phillips SF, Zinsmeister AR. Eosinophilic gastroenteritis: a clinicopathological study of patients with disease of the mucosa, muscle layer, and subserosal tissues. Gut 1990; 31:54.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/4\" class=\"nounderline abstract_t\">Foroughi S, Foster B, Kim N, et al. Anti-IgE treatment of eosinophil-associated gastrointestinal disorders. J Allergy Clin Immunol 2007; 120:594.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/5\" class=\"nounderline abstract_t\">Min KU, Metcalf DD. Eosinophilic gastroenteritis. Immunol Allergy Clin North Am 1991; 11:799.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/6\" class=\"nounderline abstract_t\">Yun MY, Cho YU, Park IS, et al. Eosinophilic gastroenteritis presenting as small bowel obstruction: a case report and review of the literature. World J Gastroenterol 2007; 13:1758.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/7\" class=\"nounderline abstract_t\">Caldwell JH, Tennenbaum JI, Bronstein HA. Serum IgE in eosinophilic gastroenteritis. Response to intestinal challenge in two cases. N Engl J Med 1975; 292:1388.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/8\" class=\"nounderline abstract_t\">Klein NC, Hargrove RL, Sleisenger MH, Jeffries GH. Eosinophilic gastroenteritis. Medicine (Baltimore) 1970; 49:299.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/9\" class=\"nounderline abstract_t\">Katz AJ, Goldman H, Grand RJ. Gastric mucosal biopsy in eosinophilic (allergic) gastroenteritis. Gastroenterology 1977; 73:705.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/10\" class=\"nounderline abstract_t\">Landres RT, Kuster GG, Strum WB. Eosinophilic esophagitis in a patient with vigorous achalasia. Gastroenterology 1978; 74:1298.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/11\" class=\"nounderline abstract_t\">Chehade M, Magid MS, Mofidi S, et al. Allergic eosinophilic gastroenteritis with protein-losing enteropathy: intestinal pathology, clinical course, and long-term follow-up. J Pediatr Gastroenterol Nutr 2006; 42:516.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/12\" class=\"nounderline abstract_t\">Chen MJ, Chu CH, Lin SC, et al. Eosinophilic gastroenteritis: clinical experience with 15 patients. World J Gastroenterol 2003; 9:2813.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/13\" class=\"nounderline abstract_t\">Gonsalves N, Doerfler B, Yang G, et al. A prospective clinical trial of six food elimination diet or elemental diet in the treatment of adults with eosinophilic gastroenteritis (abstract). Gastroenterology 2009; 136:S1861.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/14\" class=\"nounderline abstract_t\">Ko HM, Morotti RA, Yershov O, Chehade M. Eosinophilic gastritis in children: clinicopathological correlation, disease course, and response to therapy. Am J Gastroenterol 2014; 109:1277.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/15\" class=\"nounderline abstract_t\">Prussin C, Lee J, Foster B. Eosinophilic gastrointestinal disease and peanut allergy are alternatively associated with IL-5+ and IL-5(-) T(H)2 responses. J Allergy Clin Immunol 2009; 124:1326.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/16\" class=\"nounderline abstract_t\">Hogan SP, Mishra A, Brandt EB, et al. A critical role for eotaxin in experimental oral antigen-induced eosinophilic gastrointestinal allergy. Proc Natl Acad Sci U S A 2000; 97:6681.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/17\" class=\"nounderline abstract_t\">Desreumaux P, Bloget F, Seguy D, et al. Interleukin 3, granulocyte-macrophage colony-stimulating factor, and interleukin 5 in eosinophilic gastroenteritis. Gastroenterology 1996; 110:768.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/18\" class=\"nounderline abstract_t\">Talley NJ, Kephart GM, McGovern TW, et al. Deposition of eosinophil granule major basic protein in eosinophilic gastroenteritis and celiac disease. Gastroenterology 1992; 103:137.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/19\" class=\"nounderline abstract_t\">Schoonbroodt D, Horsmans Y, Laka A, et al. Eosinophilic gastroenteritis presenting with colitis and cholangitis. Dig Dis Sci 1995; 40:308.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/20\" class=\"nounderline abstract_t\">Haberkern CM, Christie DL, Haas JE. Eosinophilic gastroenteritis presenting as ileocolitis. Gastroenterology 1978; 74:896.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/21\" class=\"nounderline abstract_t\">Matsushita M, Hajiro K, Morita Y, et al. Eosinophilic gastroenteritis involving the entire digestive tract. Am J Gastroenterol 1995; 90:1868.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/22\" class=\"nounderline abstract_t\">Cello JP. Eosinophilic gastroenteritis--a complex disease entity. Am J Med 1979; 67:1097.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/23\" class=\"nounderline abstract_t\">MacCarty RL, Talley NJ. Barium studies in diffuse eosinophilic gastroenteritis. Gastrointest Radiol 1990; 15:183.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/24\" class=\"nounderline abstract_t\">Man F, Chiocca JC. Achalasia due to eosinophil infiltration: fact or fiction? Dig Dis Sci 1993; 38:1561.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/25\" class=\"nounderline abstract_t\">Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 20-1992. A 24-year-old man with asthma and bouts of epigastric pain, nausea, and vomiting. N Engl J Med 1992; 326:1342.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/26\" class=\"nounderline abstract_t\">Chang JY, Choung RS, Lee RM, et al. A shift in the clinical spectrum of eosinophilic gastroenteritis toward the mucosal disease type. Clin Gastroenterol Hepatol 2010; 8:669.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/27\" class=\"nounderline abstract_t\">Lee CM, Changchien CS, Chen PC, et al. Eosinophilic gastroenteritis: 10 years experience. Am J Gastroenterol 1993; 88:70.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/28\" class=\"nounderline abstract_t\">Lee M, Hodges WG, Huggins TL, Lee EL. Eosinophilic gastroenteritis. South Med J 1996; 89:189.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/29\" class=\"nounderline abstract_t\">Leinbach GE, Rubin CE. Eosinophilic gastroenteritis: a simple reaction to food allergens? Gastroenterology 1970; 59:874.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/30\" class=\"nounderline abstract_t\">Walker NI, Croese J, Clouston AD, et al. Eosinophilic enteritis in northeastern Australia. Pathology, association with Ancylostoma caninum, and implications. Am J Surg Pathol 1995; 19:328.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/31\" class=\"nounderline abstract_t\">Fauci AS, Harley JB, Roberts WC, et al. NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med 1982; 97:78.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/32\" class=\"nounderline abstract_t\">Blackshaw AJ, Levison DA. Eosinophilic infiltrates of the gastrointestinal tract. J Clin Pathol 1986; 39:1.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/33\" class=\"nounderline abstract_t\">Spergel JM, Shuker M. Nutritional management of eosinophilic esophagitis. Gastrointest Endosc Clin N Am 2008; 18:179.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/34\" class=\"nounderline abstract_t\">Kagalwalla AF, Sentongo TA, Ritz S, et al. Effect of six-food elimination diet on clinical and histologic outcomes in eosinophilic esophagitis. Clin Gastroenterol Hepatol 2006; 4:1097.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/35\" class=\"nounderline abstract_t\">American Gastroenterological Association medical position statement: guidelines for the evaluation of food allergies. Gastroenterology 2001; 120:1023.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/36\" class=\"nounderline abstract_t\">Tan AC, Kruimel JW, Naber TH. Eosinophilic gastroenteritis treated with non-enteric-coated budesonide tablets. Eur J Gastroenterol Hepatol 2001; 13:425.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/37\" class=\"nounderline abstract_t\">Siewert E, Lammert F, Koppitz P, et al. Eosinophilic gastroenteritis with severe protein-losing enteropathy: successful treatment with budesonide. Dig Liver Dis 2006; 38:55.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/38\" class=\"nounderline abstract_t\">Elsing C, Placke J, Gross-Weege W. Budesonide for the treatment of obstructive eosinophilic jejunitis. Z Gastroenterol 2007; 45:187.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/39\" class=\"nounderline abstract_t\">Van Dellen RG, Lewis JC. Oral administration of cromolyn in a patient with protein-losing enteropathy, food allergy, and eosinophilic gastroenteritis. Mayo Clin Proc 1994; 69:441.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/40\" class=\"nounderline abstract_t\">P&eacute;rez-Mill&aacute;n A, Mart&iacute;n-Lorente JL, L&oacute;pez-Morante A, et al. Subserosal eosinophilic gastroenteritis treated efficaciously with sodium cromoglycate. Dig Dis Sci 1997; 42:342.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/41\" class=\"nounderline abstract_t\">Melamed I, Feanny SJ, Sherman PM, Roifman CM. Benefit of ketotifen in patients with eosinophilic gastroenteritis. Am J Med 1991; 90:310.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/42\" class=\"nounderline abstract_t\">Katsinelos P, Pilpilidis I, Xiarchos P, et al. Oral administration of ketotifen in a patient with eosinophilic colitis and severe osteoporosis. Am J Gastroenterol 2002; 97:1072.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/43\" class=\"nounderline abstract_t\">Bolukbas FF, Bolukbas C, Uzunkoy A, et al. A dramatic response to ketotifen in a case of eosinophilic gastroenteritis mimicking abdominal emergency. Dig Dis Sci 2004; 49:1782.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/44\" class=\"nounderline abstract_t\">Neustrom MR, Friesen C. Treatment of eosinophilic gastroenteritis with montelukast. J Allergy Clin Immunol 1999; 104:506.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/45\" class=\"nounderline abstract_t\">Schwartz DA, Pardi DS, Murray JA. Use of montelukast as steroid-sparing agent for recurrent eosinophilic gastroenteritis. Dig Dis Sci 2001; 46:1787.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/46\" class=\"nounderline abstract_t\">Quack I, Sellin L, Buchner NJ, et al. Eosinophilic gastroenteritis in a young girl--long term remission under Montelukast. BMC Gastroenterol 2005; 5:24.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/47\" class=\"nounderline abstract_t\">Daikh BE, Ryan CK, Schwartz RH. Montelukast reduces peripheral blood eosinophilia but not tissue eosinophilia or symptoms in a patient with eosinophilic gastroenteritis and esophageal stricture. Ann Allergy Asthma Immunol 2003; 90:23.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/48\" class=\"nounderline abstract_t\">Shirai T, Hashimoto D, Suzuki K, et al. Successful treatment of eosinophilic gastroenteritis with suplatast tosilate. J Allergy Clin Immunol 2001; 107:924.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/49\" class=\"nounderline abstract_t\">Prussin C, James SP, Huber MM, et al. Pilot study of anti-IL-5 in eosinophilic gastroenteritis (abstract). J Allergy Clin Immunol 2003; 11:A.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-gastroenteritis/abstract/50\" class=\"nounderline abstract_t\">Kim YJ, Prussin C, Martin B, et al. Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700. J Allergy Clin Immunol 2004; 114:1449.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 2536 Version 15.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H11\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H775893728\" id=\"outline-link-H775893728\">DEFINITION</a></li><li><a href=\"#H259960030\" id=\"outline-link-H259960030\">EPIDEMIOLOGY</a></li><li><a href=\"#H259959758\" id=\"outline-link-H259959758\">PATHOGENESIS</a></li><li><a href=\"#H259957844\" id=\"outline-link-H259957844\">CLINICAL MANIFESTATIONS</a><ul><li><a href=\"#H2\" id=\"outline-link-H2\">Mucosal disease</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Muscular layer disease</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Subserosal disease</a></li></ul></li><li><a href=\"#H259957467\" id=\"outline-link-H259957467\">LABORATORY FINDINGS</a></li><li><a href=\"#H259957890\" id=\"outline-link-H259957890\">IMAGING FINDINGS</a></li><li><a href=\"#H273960934\" id=\"outline-link-H273960934\">EVALUATION</a><ul><li><a href=\"#H273961287\" id=\"outline-link-H273961287\">Diagnosis</a><ul><li><a href=\"#H697190562\" id=\"outline-link-H697190562\">- History and physical examination</a></li><li><a href=\"#H273960927\" id=\"outline-link-H273960927\">- Laboratory evaluation and other testing</a></li><li><a href=\"#H273961345\" id=\"outline-link-H273961345\">- Endoscopy and biopsy</a></li><li><a href=\"#H344301069\" id=\"outline-link-H344301069\">- Full-thickness biopsy</a></li></ul></li></ul></li><li><a href=\"#H259957265\" id=\"outline-link-H259957265\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H259957271\" id=\"outline-link-H259957271\">DISEASE COURSE</a></li><li><a href=\"#H860165348\" id=\"outline-link-H860165348\">MANAGEMENT</a><ul><li><a href=\"#H775893880\" id=\"outline-link-H775893880\">lnitial therapy</a><ul><li><a href=\"#H259960214\" id=\"outline-link-H259960214\">- Dietary therapy</a></li><li><a href=\"#H259960226\" id=\"outline-link-H259960226\">- Glucocorticoids</a></li></ul></li><li><a href=\"#H775893873\" id=\"outline-link-H775893873\">Recurrent symptoms</a></li><li><a href=\"#H860165540\" id=\"outline-link-H860165540\">Other therapies</a></li></ul></li><li><a href=\"#H11\" id=\"outline-link-H11\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#H2099131980\" id=\"outline-link-H2099131980\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"GAST/2536|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=GAST/50409\" class=\"graphic graphic_picture\">- Endosc eosinophil gastroent</a></li><li><a href=\"image.htm?imageKey=GAST/50254\" class=\"graphic graphic_picture\">- Biopsy eosinophil gastroent</a></li></ul></li><li><div id=\"GAST/2536|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=GAST/76166\" class=\"graphic graphic_table\">- Clinical features malabsorption</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=achalasia-pathogenesis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Achalasia: Pathogenesis, clinical manifestations, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-patient-with-unexplained-eosinophilia\" class=\"medical medical_review\">Approach to the patient with unexplained eosinophilia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss\" class=\"medical medical_review\">Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-and-diagnosis-of-malabsorption\" class=\"medical medical_review\">Clinical features and diagnosis of malabsorption</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-diagnosis-and-staging-of-gastric-cancer\" class=\"medical medical_review\">Clinical features, diagnosis, and staging of gastric cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-eosinophilic-esophagitis\" class=\"medical medical_review\">Clinical manifestations and diagnosis of eosinophilic esophagitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-polyarteritis-nodosa-in-adults\" class=\"medical medical_review\">Clinical manifestations and diagnosis of polyarteritis nodosa in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-prognosis-of-crohn-disease-in-adults\" class=\"medical medical_review\">Clinical manifestations, diagnosis and prognosis of Crohn disease in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-langerhans-cell-histiocytosis\" class=\"medical medical_review\">Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-presentation-and-diagnosis-of-primary-gastrointestinal-lymphomas\" class=\"medical medical_review\">Clinical presentation and diagnosis of primary gastrointestinal lymphomas</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=eosinophil-biology-and-causes-of-eosinophilia\" class=\"medical medical_review\">Eosinophil biology and causes of eosinophilia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hypereosinophilic-syndromes-clinical-manifestations-pathophysiology-and-diagnosis\" class=\"medical medical_review\">Hypereosinophilic syndromes: Clinical manifestations, pathophysiology, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=major-side-effects-of-systemic-glucocorticoids\" class=\"medical medical_review\">Major side effects of systemic glucocorticoids</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-treatment-of-malabsorption\" class=\"medical medical_review\">Overview of the treatment of malabsorption</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pleural-fluid-eosinophilia\" class=\"medical medical_review\">Pleural fluid eosinophilia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=protein-losing-gastroenteropathy\" class=\"medical medical_review\">Protein-losing gastroenteropathy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-eosinophilic-esophagitis\" class=\"medical medical_review\">Treatment of eosinophilic esophagitis</a></li></ul></div></div>","javascript":null}